Last edition
News about "Nabota"
South Korea-based Daewoong Pharma to invest $74.6 M to produce botulinum toxin product Nabota
The facility is set to be built in Hwaseong, Gyeonggi Province
Nabota | 09/05/2023 | By Sudeep Soparkar | 959
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members